0001209191-20-056071.txt : 20201028 0001209191-20-056071.hdr.sgml : 20201028 20201028160237 ACCESSION NUMBER: 0001209191-20-056071 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20201028 FILED AS OF DATE: 20201028 DATE AS OF CHANGE: 20201028 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Durgam Suresh K. CENTRAL INDEX KEY: 0001829958 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36274 FILM NUMBER: 201268623 MAIL ADDRESS: STREET 1: C/O INTER-CELLULAR THERAPIES, INC. STREET 2: 430 EAST 29TH STREET CITY: NEW YORK STATE: NY ZIP: 10016 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Intra-Cellular Therapies, Inc. CENTRAL INDEX KEY: 0001567514 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 364742850 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 430 EAST 29TH STREET CITY: NEW YORK STATE: NY ZIP: 10016 BUSINESS PHONE: 212-923-3344 MAIL ADDRESS: STREET 1: 430 EAST 29TH STREET CITY: NEW YORK STATE: NY ZIP: 10016 FORMER COMPANY: FORMER CONFORMED NAME: Oneida Resources Corp. DATE OF NAME CHANGE: 20130122 3 1 doc3.xml FORM 3 SUBMISSION X0206 3 2020-10-28 0 0001567514 Intra-Cellular Therapies, Inc. ITCI 0001829958 Durgam Suresh K. C/O INTRA-CELLULAR THERAPIES, INC. 430 EAST 29TH STREET NEW YORK NY 10016 0 1 0 0 Chief Medical Officer Common Stock 8759 D Stock Option (right to buy) 0.00 2028-08-15 Common Stock 62282 D Stock Option (right to buy) 0.00 2029-01-08 Common Stock 53967 D Stock Option (right to buy) 0.00 2030-02-18 Common Stock 33443 D Restricted Stock Units 0.00 Common Stock 26185 D Restricted Stock Units 0.00 Common Stock 25062 D On August 15, 2018, the reporting person was granted options to purchase 62,282 shares of common stock, vesting in three equal annual installments beginning on the first anniversary of the grant date. On January 8, 2019, the reporting person was granted options to purchase 53,967 shares of common stock, vesting in three equal annual installments beginning on the first anniversary of the grant date. On February 18, 2020, the reporting person was granted options to purchase 33,443 shares of common stock, vesting in three equal annual installments beginning on the first anniversary of the grant date. On January 8, 2019, the reporting person was granted 39,277 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date. On February 18, 2020, the reporting person was granted 25,062 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date. Exhibit 24.1 - Power of Attorney /s/ Lawrence J. Hineline, Attorney-in-fact 2020-10-28 EX-24.1 2 attachment1.htm EX-24.1 DOCUMENT

POWER OF ATTORNEY

Know all by these presents, that the undersigned hereby constitutes and appoints
Sharon Mates, Ph.D., Chairman, President and Chief Executive Officer of
Intra-Cellular Therapies, Inc. (the "Company"), Lawrence J. Hineline, Senior
Vice President of Finance and Chief Financial Officer of the Company, Michael I.
Halstead, Executive Vice President and General Counsel of the Company, and
Allyson Wilkinson and Amanda Mei of Mintz, Levin, Cohn, Ferris, Glovsky and
Popeo, P.C., signing singly, with full power of substitution, the undersigned's
true and lawful attorney-in-fact to:

	(1)	execute for and on behalf of the undersigned, forms and authentication
documents for EDGAR Filing Access;
	(2)	do and perform any and all acts for and on behalf of the undersigned which
may be necessary or desirable to complete and execute any such forms and
authentication documents;
	(3) 	execute for and on behalf of the undersigned, in the undersigned's
capacity as an officer, director and/or 10% shareholder of the Company, Forms 3,
4 and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934
and the rules thereunder;
	(4)	do and perform any and all acts for and on behalf of the undersigned which
may be necessary or desirable to complete and execute any such Form 3, 4 or 5
and timely file such form with the United States Securities and Exchange
Commission and any stock exchange or similar authority; and
	(5)	take any other action of any type whatsoever in connection with the
foregoing which, in the opinion of such attorney-in-fact, may be of benefit to,
in the best interest of, or legally required by, the undersigned, it being
understood that the documents executed by such attorney-in-fact, on behalf of
the undersigned pursuant to this Power of Attorney, shall be in such form and
shall contain such terms and conditions as such attorney-in-fact may approve in
such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and
authority to do and perform any and every act and thing whatsoever requisite,
necessary, or proper to be done in the exercise of any of the rights and powers
herein granted, as fully to all intents and purposes as the undersigned might or
could do if personally present, with full power of substitution or revocation,
hereby ratifying and confirming all that such attorney-in-fact, or such
attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be
done by virtue of this power of attorney and the rights and powers herein
granted.  The undersigned acknowledges that the foregoing attorneys-in-fact, in
serving in such capacity at the request of the undersigned, is not assuming, nor
is the Company assuming, any of the undersigned's responsibilities to comply
with Section 16 of the Securities Exchange Act of 1934.

This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file Forms 3, 4 and 5 with respect to the
undersigned's holdings of and transactions in securities issued by the Company,
unless earlier revoked by the undersigned in a signed writing delivered to the
foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be
executed this 28th day of October 2020.


						/s/ Suresh Durgam
						Suresh Durgam